Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
, 10, 1342
eCollection

Hemolytic Anemia and Reactive Thrombocytosis Associated With Cefoperazone/Sulbactam

Affiliations
Case Reports

Hemolytic Anemia and Reactive Thrombocytosis Associated With Cefoperazone/Sulbactam

Ling Zhou et al. Front Pharmacol.

Abstract

Background: Cefoperazone/sulbactam is a broad-spectrum antibacterial agent. Drug-induced immune hemolytic anemia is a rare but serious condition, and reactive thrombocytosis is caused by processes extrinsic to the megakaryocyte. Limited data are available for cefoperazone/sulbactam-associated hemolytic anemia and reactive thrombocytosis. Case presentation: We report the case of a 60-year-old woman undergoing surgical excision of the left atrial myxoma, who presented with hemolytic anemia and thrombocytosis following cefoperazone/sulbactam administration for lung infection. The duration of cefoperazone/sulbactam therapy was 8 days. Blood analysis showed markedly decreased hemoglobin, hematocrit, and red blood cell levels, with elevated lactate dehydrogenase, indirect bilirubin, platelets, and reticulocytes. Furthermore, the direct antiglobulin test was positive for anti-C3 and a diagnosis of hemolytic anemia and reactive thrombocytosis was made. Then, cefoperazone/sulbactam was discontinued and red blood cell transfusion was performed for 3 days. After 1 week, the patient's condition improved, and she was discharged. Conclusion: This is the first suspected case report of immune hemolytic anemia and reactive thrombocytosis related to cefoperazone/sulbactam. Caution should be taken for this reaction in patients undergoing cefoperazone/sulbactam therapy.

Keywords: adverse reaction; cefoperazone/sulbactam; immune hemolytic anemia; probable; reactive thrombocytosis.

Figures

Figure 1
Figure 1
Serial changes of complete blood count during cefoperazone/sulbactam therapy and withdrawal. SCF, Cefoperazone/sulbactam; Hb, hemoglobin; RBC, Red blood cell; Hct, Hematocrit; PLT, Platelet.

Similar articles

See all similar articles

References

    1. Arndt P. A. (2014). Drug-induced immune hemolytic anemia: the last 30 years of changes. Immunohematology 30, 44–54. - PubMed
    1. Baek E. J., Lee S., Kim S., Choi H. K., Kim H. O. (2009). A case of immune hemolytic anemia induced by ceftizoxime and cefobactam (sulbactam/cefoperazone). Korean J. Lab. Med. 29, 578–584. 10.3343/kjlm.2009.29.6.578 - DOI - PubMed
    1. Chinese Society of Hematology, Chinese Medical Association (2017). Chinese consensus on the diagnosis and treatment of autoimmune hemolytic anemia. Chin. J. Hematol. 38, 265–267. - PubMed
    1. Gao C., Tong J., Yu K., Sun Z., An R., Du Z. (2016). Pharmacokinetics of cefoperazone/sulbactam in critically ill patients receiving continuous venovenous hemofiltration. Eur. J. Clin. Pharmacol. 72, 823–830. 10.1007/s00228-016-2045-x - DOI - PubMed
    1. Garbe E., Andersohn F., Bronder E., Klimpel A., Thomae M., Schrezenmeier H., et al. (2011). Drug induced immune haemolytic anaemia in the Berlin Case-Control Surveillance Study. Br. J. Haematol. 154, 644–653. 10.1111/j.1365-2141.2011.08784.x - DOI - PubMed

Publication types

Feedback